Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 9/2010

01-09-2010 | Meeting Report

CIMT 2009: report on the seventh annual meeting of the association for immunotherapy of cancer

June 3–5, Mainz, Germany

Authors: Mustafa Diken, Melanie Widenmeyer, Cécile Gouttefangeas, Marij J. P. Welters, Cedrik M. Britten

Published in: Cancer Immunology, Immunotherapy | Issue 9/2010

Login to get access

Excerpt

CIMT 2009 was the seventh annual meeting organized by the Cancer Immunotherapy (CIMT) Association and attracted an audience of about 400 international scientists to meet in Mainz and discuss recent developments in the field of cancer immunotherapy. Focus of this year’s meeting were basic and translational aspects of antigen-specific immunotherapy and the monitoring of immune responses with three dedicated sessions organized by the recently founded committee of the CIMT Immunoguiding Program (CIP). The newly initiated CIMT working group on regulatory research organized a session dedicated to regulatory aspects of drug development in which perspectives from academia, consultants, industry and regulatory authorities were presented. The current meeting report summarizes selected presentations providing a broad overview on the scientific content covered at the meeting. …
Metadata
Title
CIMT 2009: report on the seventh annual meeting of the association for immunotherapy of cancer
June 3–5, Mainz, Germany
Authors
Mustafa Diken
Melanie Widenmeyer
Cécile Gouttefangeas
Marij J. P. Welters
Cedrik M. Britten
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 9/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0770-z

Other articles of this Issue 9/2010

Cancer Immunology, Immunotherapy 9/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine